Patent 12447128

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Douglas Alan Lorenz (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Sanjay Konagurthu (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Randy J. Wald (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Jason A. Everett (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Sheila Matz (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Yuuki Takaishi (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Toshiro Sakai (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Ryousuke Irie (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Shinsuke Oba (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Hiroyasu Toyota (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Koji Nishimura (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)
  • Atsushi Kanbayashi (Astellas Pharma Inc, Medivation Prostate Therapeutics LLC)

Original assignee

Astellas Pharma Inc and Medivation Prostate Therapeutics LLC are listed as the original co-assignees on the patent.

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company that develops, manufactures, and sells pharmaceutical products. They ship products embodying the claims, specifically XTANDI® (enzalutamide) soft capsules. Medivation Prostate Therapeutics LLC appears to be a subsidiary of Medivation, Inc., which was acquired by Pfizer in 2016 and was focused on developing therapies for prostate cancer. Given the acquisition of Medivation by Pfizer, Medivation Prostate Therapeutics LLC is likely no longer an independent operating entity and its assets, including patents, would have been integrated into Pfizer's portfolio.

Assignment timeline

The USPTO Patent Assignment Search for US patent 12447128 currently shows no recorded assignments. This indicates that the ownership of the patent remains with the original assignees, Astellas Pharma Inc. and Medivation Prostate Therapeutics LLC, as granted.

Timeline diagram

timeline
    title Ownership of US 12447128
    2012 : Priority date
    2022 : Application filed by Astellas Pharma Inc, Medivation Prostate Therapeutics LLC
    2025 : Granted to Astellas Pharma Inc, Medivation Prostate Therapeutics LLC

NPE / troll-pattern signals

  1. Shell-entity transfer — not present
  2. Known asserter in the chain — not present
  3. Repeat correspondent across the chain — not present
  4. Cascading transfers — not present
  5. Pre-litigation transfer — not present
  6. Bankruptcy fire-sale — unclear (Medivation, LLC was acquired by Pfizer, which means its assets, including patents, would have transferred. However, this is an acquisition, not a bankruptcy fire-sale of Astellas Pharma Inc. The specific status of Medivation Prostate Therapeutics LLC's patent holdings post-acquisition isn't explicitly detailed as a separate transfer event in the assignment records for this patent.)
  7. Privateering — not present
  8. Defensive aggregator (anti-NPE) — not present

Verdict

Insufficient data
There are no recorded assignments for US patent 12447128 in the USPTO Assignment Center. Without any transfer records, it is not possible to identify any NPE or patent-troll patterns. The patent remains with the original co-assignees, Astellas Pharma Inc. and Medivation Prostate Therapeutics LLC, as of the grant date (2025-10-21).

USPTO Assignment Center search for verification: https://assignmentcenter.uspto.gov/

Generated 5/31/2026, 6:45:54 AM